Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
Chun­yan Shi, Yan Wang, Jianxin Xue, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17

Showing 17 citing articles:

Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 49
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 34, pp. 4029-4039
Closed Access | Times Cited: 47
Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma
Fenge Li, Huancheng Wu, Xueming Du, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1460-1460
Open Access | Times Cited: 11
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Ross A. Soo, Filippo de Marinis, Ji‐Youn Han, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 1, pp. 80-84
Open Access | Times Cited: 11
Shifting cold to hot tumors by nanoparticle-loaded drugs and products
Irfan Ahmad, Kamil K. Atiyah Altameemi, Mohaned Mohammed Hani, et al.
Clinical & Translational Oncology (2024)
Closed Access | Times Cited: 4
EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment
Qianqian Chen, Liliang Xia, Jingze Wang, et al.
Lung Cancer (2024) Vol. 192, pp. 107815-107815
Open Access | Times Cited: 3
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer
Sun Min Lim, Stefanie S. Schalm, Eun Ji Lee, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 3
Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
Yi Dong, L Khan, Yi Yao
Journal of the National Cancer Center (2024) Vol. 4, Iss. 4, pp. 289-298
Open Access | Times Cited: 2
Strategies for engineering oncolytic viruses to enhance cancer immunotherapy
Ziyang Steve Yin, Zhengfeng Wang
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1(‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort
Ruolan Xia, Yanying Li, Ling Yang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 13, pp. 14282-14292
Open Access | Times Cited: 4
[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to 
Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].
Jiamo Li, Xingyu Yao, Longjue Qiu, et al.
PubMed (2023) Vol. 26, Iss. 5, pp. 392-399
Closed Access | Times Cited: 1
ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinoma
Sarah Laing, Björn Kruspig, Robin Shaw, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Brian J. Thomas, Sania Zafar Awan, Trupti Joshi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors
Hyung‐Don Kim, Min‐Hee Ryu, Young Soo Park, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 13, pp. 2743-2750
Closed Access
Global implementation of individualized lung cancer care requires wide adoption of molecular tumor profiling
Nathaniel Deboever, Mara B. Antonoff
Journal of Thoracic Disease (2024) Vol. 16, Iss. 4, pp. 2698-2701
Open Access
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Brian J. Thomas, Sania Zafar Awan, Trupti Joshi, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
Cheng‐Yu Chang, Chung‐Yu Chen, Shih‐Chieh Chang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access
Page 1

Scroll to top